EGFR and lung carcinoma: However, these treatments can cost up to $1 million per patient, limiting their use globally.11 Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) commonly used in lung cancer with brain metastases, can cost up to $500 000 annually.